Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 376Neoplasm Metastasis 21Neoplasms 11Advanced Breast Cancer 10Carcinoma, Intraductal, Noninfiltrating 8Triple Negative Breast Neoplasms 7Osteoporosis 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Breast Diseases 7Breast Carcinoma In Situ 6Carcinoma, Lobular 5Prostatic Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Arthralgia 4Recurrence 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Squamous Cell Carcinoma of Head and Neck 2Pain 2Obesity 2Neoplasms by Site 2Multiple Endocrine Neoplasia Type 1 2Infertility 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2HR Positive HER2 Negative Advanced Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Endometrial Neoplasms 2

Interventions

palbociclib 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer (Female) × Letrozole × Breast × Clear all
NCT02142868 2018-12-21

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Pfizer

No longer available
Breast

Advanced Breast Cancer (Female)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡